Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of trontinemab in cognitively unimpaired individuals at risk of progressing to symptomatic Alzheimer's disease
CTR20262874Phase 3Active
- Sponsor
- Roche
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trontinemab in Alzheimer's disease (AD), sponsored by Roche. Started Aug 2026; status: active.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20262874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262874.